

## RÉSUMÉ DIGEST

**ACT 125 (HB 403)**

**2023 Regular Session**

**Brown**

Existing law establishes certain requirements for a health coverage plan that utilizes step therapy or fail first protocols.

Existing law does not prohibit a health coverage plan's substitution of an AB-rated generic equivalent or interchangeable biological product as designated by the U.S. Food and Drug Administration (FDA).

New law adds that a health coverage plan is not prohibited from substituting a biosimilar biological product as designated by the FDA. Otherwise retains existing law.

Effective August 1, 2023.

(Amends R.S. 22:1053(A)(2))